RemeGen Ltd.
https://remegen.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From RemeGen Ltd.
RemeGen Rises, Falls Along With Chinese Antibody Ambitions
Everything seemed to be aligned for success, but shares in leading Chinese antibody developer RemeGen recently dropped by nearly 40%, reflecting a range of internal and external likely factors.
China Sets Clinical Trial Record But Starting Studies Can Be Challenging
Antibody-drug conjugates, GLP-1 receptor agonists and cell/gene therapies propelled a big increase in clinical trial registrations in China last year, but why do sponsors sometimes remain reluctant to actually start studies?
Chinese ADC Developers Forge Domestic Alliances To Push R&D
To date, nine major pairs of antibody and payload-linker platform makers based in China are making a concerted approach for ADC research and development, research by Scrip reveals.
ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice